Market Currents
Johnson & Johnson (JNJ) says it expects to incur a special charge in Q2 of ~$600M to...
-
Friday, June 8, 2012, 4:59 PM ETJohnson & Johnson (JNJ) says it expects to incur a special charge in Q2 of ~$600M to increase its accrual for the potential settlement of previously disclosed civil litigation matters related to Risperdal, Invega, Natrecor and Omnicare (OCR).
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
